Dong-A ST’s new diabetes treatment drug ‘SUGANON’ (Main ingredient: Evogliptin), a DPP-4 inhibitor class developed independently [사진=동아ST 제공]
[헬스코리아뉴스 / 이순호] Research results have shown that ‘Suganon’, a new diabetes drug developed by Dong-A ST, can be developed as an anti-inflammatory agent. In animal tests, it showed anti-inflammatory and pain-relieving effects similar to non-steroidal anti-inflammatory drugs (NSAIDs), raising expectations for expanded indications.
A joint research team consisting of Professor Pyeong-gu Cho of the Department of Neurosurgery at Ajou University Hospital, Professor Dong-ah Shin of the Department of Neurosurgery at Yonsei University Severance Hospital, and Professor Min-cheol Jang of the Department of Rehabilitation Medicine at Yeungnam University Hospital recently published a paper containing these research results in the international academic journal ‘Biomedicines’. The title of the paper is ‘The Effect of Evogliptin Tartrate on Controlling Inflammatory Pain’.
Evogliptin tartrate (hereinafter referred to as Evogliptin) is the main ingredient in ‘Suganon’, a type 2 diabetes treatment developed by Dong-A ST. It is a component of the mechanism that inhibits dipeptidyl peptidase-4 (DPP-4) and enhances the secretion of incretin hormones, including glucagon-like peptide-1 (GLP-1). Elevated levels of GLP-1 lead to various inflammatory cytokines. It is known to reduce the production of caine. This is why the research team set out to confirm the anti-inflammatory effect of evogliptin.
The research team compared a total of 39 mice in four groups: a negative control group (naive), a group that induced plantar inflammation and administered evogliptin (CFAE), a group that induced plantar inflammation and administered a placebo (CFAV), and a group that induced plantar inflammation and administered indomethacin (CFAI). The test was conducted over 5 days, divided into groups.
In inflammation-induced mice, an inflammatory response was induced in the soles of the feet, causing swelling, and the thickness of the soles increased accordingly. Afterwards, when evogliptin, placebo, and indomethacin were administered respectively, the sole thickness of the evogliptin and indomethacin groups was significantly reduced compared to the negative control group and the placebo group. There was no significant difference in the effect of reducing sole thickness between the evogliptin-treated group and the indomethacin-treated group.
Paw withdrawal threshold (PWT), which was significantly lowered due to the induction of footpad inflammation, significantly increased in the evogliptin-administered group compared to the placebo-administered group from the second day of drug administration.
PWT is an electronic measurement of the load at which a rat feels pain on the sole of its foot. As the value increases, it means that inflammatory pain is alleviated. There was no significant difference in the analgesic effect of the evogliptin-administered group against inflammatory pain compared to the indomethacin-administered group.
The level of inflammatory cytokines, which can most directly confirm the inflammatory response, was also significantly reduced in the evogliptin treatment group. In inflammation-induced mice, the cytokine levels (TNF-α and IL-β) were measured to be significantly higher in both paw tissue and serum. The cytokine levels in mice administered evogliptin were significantly decreased compared to the placebo group, showing an anti-inflammatory effect. Confirmed.
The research team said, “The purpose of this study was to confirm the possibility of expanding the indications for evogliptin for patients with inflammatory pain.” “The results of the study showed that evogliptin has a beneficial effect on suppressing inflammation and relieving pain caused by inflammation. “It appeared,” he explained.
“In particular, similar to the effect of indomethacin, it showed a beneficial effect in reducing inflammation and improving inflammatory pain,” he said. “The exact mechanism by which evogliptin regulates the anti-inflammatory effect has not yet been comprehensively confirmed, but these findings are related to inflammation. “It comprehensively suggests the potential of the drug as a therapeutic intervention for these conditions,” he emphasized.
Meanwhile, this study was conducted with support from the Korea Institute of Science and Technology’s joint research project, and is evaluated to have higher objectivity in that Dong-A ST, which developed and sells ‘Suganon’, did not directly participate in the study.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
2023-11-13 15:03:00
#Confirmed #possibility #expansion #antiinflammatory #indications #DongA #STs #diabetes #drug #Suganon
